1159977-65-7

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromoimidazo[1,2-b]pyridazine-3-carboxamide is used as a potential anti-cancer agent for its ability to inhibit the protein kinase PDK1. This inhibition targets the PI3K/Akt signaling pathway, which is often dysregulated in cancer, leading to promising anti-tumor activity in preclinical studies.
Used in Cancer Research:
6-Bromoimidazo[1,2-b]pyridazine-3-carboxamide is used as a research tool to study the role of PDK1 in the PI3K/Akt signaling pathway and its potential as a therapeutic target for cancer treatment. Its unique structure and biological activity make it a valuable compound for further investigation and drug development in the field of oncology.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 59489-71-3 5-amino-2-bromopyrazine 
• 88497-27-2 6-bromopyridazin-3-amine 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 107-20-0 2-chloroethanal 

Downstream Products

• 1609565-36-7 2,4-difluoro-N-(5-(3-(3-hydroxy-3-methylbut-1-yn-1-yl)imidazo[1,2-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1609565-38-9 N-(5-(3-bromoimidazo[1,2-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1609565-37-8 2,4-difluoro-N-(5-(imidazo[1,2-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1609565-35-6 2,4-difluoro-N-(5-(3-(3-hydroxybut-1-yn-1-yl)imidazo[1,2-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1609565-34-5 2,4-difluoro-N-(5-(3-(3-hydroxyprop-1-yn-1-yl)imidazo[1,2-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1609565-32-3 N-(5-(3-ethynylimidazo[1,2-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1609565-33-4 2,4-difluoro-N-(2-methoxy-5-(3-((trimethylsilyl)ethynyl)imidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1609565-29-8 N-(2-chloro-5-(3-ethynylimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1609565-30-1 N-(2-chloro-5-(3-((trimethylsilyl)ethynyl)imidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1609565-26-5 4-fluoro-N-(2-methoxy-5-(3-(prop-1-yn-1-yl)imidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1609565-24-3 4-fluoro-N-(5-(3-(3-hydroxy-3-methylbut-1-yn-1-yl)imidazo[1,2-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1609565-22-1 4-fluoro-N-(5-(3-(3-hydroxybut-1-yn-1-yl)imidazo[1,2-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1609565-20-9 4-fluoro-N-(5-(3-(3-hydroxyprop-1-yn-1-yl)imidazo[1,2-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1609565-16-3 N-(5-(3-ethynylimidazo[1,2-b]pyridazin-6-yl)-2-methoxypyridin-3-yl)-4-fluorobenzenesulfonamide 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors

Mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) are located at the meeting-point of ERK and p38 MAPK signaling pathways, which can phosphorylate eukaryotic translation initiation factor 4E (eIF4E) at the conserved serine 209 exclusively. MNKs modulate the translation of mRNA involved in tumor-associated signaling pathways. Consequently, selective inhibitors of MNK1/2 could reduce the level of phosphorylated eIF4E. Series of imidazopyrazines, imidazopyridazines and imidazopyridines derivatives were synthesized and evaluated as MNK1/2 inhibitors. Several compounds exhibited great inhibitory activity against MNK1/2 and selected compounds showed moderate to excellent anti-proliferative potency against diffuse large B-cell lymphoma (DLBCL) cell lines. In particular, compound II-5 (MNK1 IC50 = 2.3 nM; MNK2 IC50 = 3.4 nM) exhibited excellent enzymatic inhibitory potency and proved to be the most potent compound against TMD-8 and DOHH-2 cell lines with IC50 value of 0.3896 μM and 0.4092 μM respectively. These results demonstrated that compound II-5 could be considered as a potential MNK1/2 inhibitor for further investigation.

Synthesis method of 6-bromoimidazo[1,2-b]pyridazine

The invention relates to a synthesis method of 6-bromoimidazo[1,2-b]pyridazine. The synthesis method includes subjecting 3-amino-6-bromopyridazine and a 40% chloroacetaldehyde solution, serving as raw materials, in a solvent to continuous reaction at 30-100 DEG C under the action of alkali, performing ethyl acetate extraction, water washing, anhydrous sodium sulfate drying and rotary evaporation and concentration to obtain a crude product of the 6-bromoimidazo[1,2-b]pyridazine, and recrystallizing the crude product to obtain a pure product. The synthesis method is easily available to raw materials, reasonable in price, free of heavy metals and corrosive gas in preparation reaction, mild in reaction and high in reaction yield and purity, has no special requirements on reaction equipment, and can be implemented through common corrosion-resistant equipment.

HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE

The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.